One mouse, one patient paradigm: New avatars of personalized cancer therapy

Cancer Letters

Volumn 344, Issue 1, 2014, Pages 1-12

  Malaney, Prerna ^a   Nicosia, Santo V ^a   Davé, Vrushank ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Co clinical Trial; Drug discovery; Genetically engineered mouse models; Mouse Avatars; Personalized medicine; Xenograft models

Indexed keywords

3 OXO 5 ALPHA STEROID 4 DEHYDROGENASE 1; BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PERTUZUMAB; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE LKB1; SELUMETINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS PROTEIN ASSOCIATED FACTOR 1;

ANDROGEN DEPRIVATION THERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CO CLINICAL TRIAL; CRYOPRESERVATION; DRUG EFFICACY; GENETICALLY ENGINEERED MOUSE STRAIN; GLIOBLASTOMA; HUMAN; LKB1 GENE; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; MOUSE MODEL; NONHUMAN; ONCOGENE K RAS; PERSONALIZED MEDICINE; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TUMOR MICROENVIRONMENT; TUMOR MODEL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ZBTB7A GENE;

ANIMALIA; MURINAE; MUS;

18-FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHY; 18FDG-PET; ACUTE PROMYELOCYTIC LEUKEMIA; APL; CO-CLINICAL TRIAL; DRUG DISCOVERY; FDA; GEMMS; GENETICALLY ENGINEERED MOUSE MODELS; GENETICALLY ENGINEREED MOUSE MODELS; HDAC; HISTONE DEACETYLASE; MATERIAL TRANSFER AGREEMENT; MOUSE AVATARS; MTA; NOD SCID GAMMA; NON-SMALL CELL LUNG CANCER; NSCLC; NSG; PATIENT-DERIVED TUMOR XENOGRAFT; PDTX; PERSONALIZED MEDICINE; THE FOOD AND DRUG ADMINISTRATION; XENOGRAFT MODELS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; MICE; MICE, TRANSGENIC; NEOPLASMS;

EID: 84893637270     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.010     Document Type: Review

References (108)

1. Hutchinson L., Kirk R. High drug attrition rates-where are we going wrongα. Nature Reviews Clinical Oncology 2011, 8:189-190.
2. Yabroff L.J., Kepka K.R., Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiology, Biomarkers and Prevention 2011, 20:2006-2014.
3. Cheon D.J., Orsulic S. Mouse models of cancer. Annual Review of Pathology: Mechanisms of Disease 2011, 6(6):95-119.
4. Walrath J.C., Hawes J.J., Van Dyke T., Reilly K.M. Genetically engineered mouse models in cancer research. Advances in Cancer Research 2010, 106:113-164.
5. Nardella C., Lunardi A., Patnaik A., Cantley L.C., Pandolfi P.P. The APL paradigm and the "co-clinical trial" project. Cancer Discovery 2011, 1:108-116.
6. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology 2012, 9:338-350.
7. Jin K.T., Teng L.S., Shen Y.P., He K.F., Xu Z.Z., Li G.L. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clinical & Translational Oncology 2010, 12:473-480.
8. Morton C.L., Houghton P.J. Establishment of human tumor xenografts in immunodeficient mice. Nature Protocol 2007, 2:247-250.
9. White R.d.V. Can Mouse Avatars guide cancer treatmentα. OncLive 2013.
10. Richmond A., Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Discovery Model Mechanisms 2008, 1:78-82.
11. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., Becker M., Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clinical Cancer Research 2008, 14:6456-6468.
12. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., Shi C., Danenberg K., Danenberg P.V., Kuramochi H., Tanaka K., Singh S., Salimi-Moosavi H., Bouraoud N., Amador M.L., Altiok S., Kulesza P., Yeo C., Messersmith W., Eshleman J., Hruban R.H., Maitra A., Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research 2006, 12:4652-4661.
13. Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., Yung R., Parmigiani G., Dorsch M., Peacock C.D., Watkins D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Research 2009, 69:3364-3373.
14. Tentler J.J., Nallapareddy S., Tan A.C., Spreafico A., Pitts T.M., Morelli M.P., Selby H.M., Kachaeva M.I., Flanigan S.A., Kulikowski G.N., Leong S., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Molecular Cancer Therapy 2010, 9:3351-3362.
15. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. Journal of National Cancer Institute 2009, 101:6-8.
16. Mueller B.M., Reisfeld R.A. Potential of the scid mouse as a host for human tumors. Cancer and Metastasis Reviews 1991, 10:193-200.
17. Sanz L., Cuesta A.M., Salas C., Corbacho C., Bellas C., Alvarez-Vallina L. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Laboratory Investigation 2009, 89:91-97.
18. Gray D.R., Huss W.J., Yau J.M., Durham L.E., Werdin E.S., Funkhouser W.K., Smith G.J. Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Research 2004, 64:1712-1721.
19. Pollack A. Seeking Cures, Patients Enlist Mice Stand-Ins 2012, The New York Times.
20. BGI launches tool for tumor xenograft research BioSpectrum 2012, BioSpectrum Bureau, China.
21. Garrido-Laguna I., Uson M., Rajeshkumar N.V., Tan A.C., de Oliveira E., Karikari C., Villaroel M.C., Salomon A., Taylor G., Sharma R., Hruban R.H., Maitra A., Laheru D., Rubio-Viqueira B., Jimeno A., Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clinical Cancer Research 2011, 17:5793-5800.
22. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
23. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proceedings of National Academy of Sciences in the United States of America 2004, 101:4966-4971.
24. Eckhardt S.G. Challenges to PDTX models in drug development. Annals of Oncology 2013, 24.
25. Kopetz S., Lemos R., Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clinical Cancer Research 2012, 18:5160-5162.
26. Giovanella B.C., Stehlin J.S., Wall M.E., Wani M.C., Nicholas A.W., Liu L.F., Silber R., Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989, 246:1046-1048.
27. BEAUTY Combines Sequencing, Avatars, Cancer, Discovery 2 (2012) 477.
28. Rowley J.D. Chromosomal patterns in myelocytic leukemia. New England Journal of Medicine 1973, 289:220-221.
29. Pandolfi P.P., Grignani F., Alcalay M., Mencarelli A., Biondi A., Lococo F., Grignani F., Pelicci P.G. Structure and origin of the acute promyelocytic leukemia Myl/Rar-alpha cdna and characterization of its retinoid-binding and transactivation properties. Oncogene 1991, 6:1285-1292.
30. He L.Z., Tribioli C., Rivi R., Peruzzi D., Pelicci P.G., Soares V., Cattoretti G., Pandolfi P.P. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proceedings of National Academy of Sciences in the United States of America 1997, 94:5302-5307.
31. Grisolano J.L., Wesselschmidt R.L., Pelicci P.G., Ley T.J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 1997, 89:376-387.
32. Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P.G., Atwater S., Bishop J.M. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proceedings of National Academy of Sciences in the United States of America 1997, 94:2551-2556.
33. Rego E.M., He L.Z., Warrell R.P., Wang Z.G., Pandolfi P.P. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proceedings of National Academy of Sciences in the United States of America 2000, 97:10173-10178.
34. Lallemand-Breitenbach V., Guillemin M.C., Janin A., Daniel M.T., Degos L., Kogan S.C., Bishop J.M., de The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. Journal of Experimental Medicine 1999, 189:1043-1052.
35. Rego E.M., Ruggero D., Tribioli C., Cattoretti G., Kogan S., Redner R.L., Pandolfi P.P. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene 2006, 25:1974-1979.
36. He L.Z., Guidez F., Tribioli C., Peruzzi D., Ruthardt M., Zelent A., Pandolfi P.P. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nature Genetics 1998, 18:126-135.
37. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell R.P., Rifkind R.A., Marks P.A., Richon V.M., Pandolfi P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. Journal of Clinical Investigation 2001, 108:1321-1330.
38. Nasr R., de The H. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. International Journal of Hematology 2010, 91:742-747.
39. Warrell R.P., He L.Z., Richon V., Calleja E., Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. Journal of the National Cancer Institute 1998, 90:1621-1625.
40. Shao W.L., Fanelli M., Ferrara F.F., Riccioni R., Rosenauer A., Davison K., Lamph W.W., Waxman S., Pelicci P.G., Lo Coco F., Avvisati G., Testa U., Peschle C., Gambacorti-Passerini C., Nervi C., Miller W.H. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute 1998, 90:124-133.
41. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., Liu Y., Tupper T., Ouyang J., Li J., Gao P., Woo M.S., Xu C., Yanagita M., Altabef A., Wang S., Lee C., Nakada Y., Pena C.G., Sun Y., Franchetti Y., Yao C., Saur A., Cameron M.D., Nishino M., Hayes D.N., Wilkerson M.D., Roberts P.J., Lee C.B., Bardeesy N., Butaney M., Chirieac L.R., Costa D.B., Jackman D., Sharpless N.E., Castrillon D.H., Demetri G.D., Janne P.A., Pandolfi P.P., Cantley L.C., Kung A.L., Engelman J.A., Wong K.K. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.
42. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., Liao M.L., Bischoff H., Reck M., Sellers M.V., Watkins C.L., Speake G., Armour A.A., Kim E.S. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. Journal of Clinical Oncology 2010, 28:744-752.
43. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., Haller A., Lothaire P., Meert A.P., Noel S., Lafitte J.J., Sculier J.P. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer 2005, 92:131-139.
44. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., Lin W.M., Province M.A., Kraja A., Johnson L.A., Shah K., Sato M., Thomas R.K., Barletta J.A., Borecki I.B., Broderick S., Chang A.C., Chiang D.Y., Chirieac L.R., Cho J., Fujii Y., Gazdar A.F., Giordano T., Greulich H., Hanna M., Johnson B.E., Kris M.G., Lash A., Lin L., Lindeman N., Mardis E.R., McPherson J.D., Minna J.D., Morgan M.B., Nadel M., Orringer M.B., Osborne J.R., Ozenberger B., Ramos A.H., Robinson J., Roth J.A., Rusch V., Sasaki H., Shepherd F., Sougnez C., Spitz M.R., Tsao M.S., Twomey D., Verhaak R.G., Weinstock G.M., Wheeler D.A., Winckler W., Yoshizawa A., Yu S., Zakowski M.F., Zhang Q., Beer D.G., Wistuba, Watson M.A., Garraway L.A., Ladanyi M., Travis W.D., Pao W., Rubin M.A., Gabriel S.B., Gibbs R.A., Varmus H.E., Wilson R.K., Lander E.S., Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
45. Steels E., Paesmans B., Berghmans T., Branle F., Lemaitre F., Mascaux C., Meert A.P., Vallot F., Lafitte J.J., Sculier J.P. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. European Respiratory Journal 2001, 18:705-719.
46. Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., Suzuki K., Nakamoto M., Shimizu E., Minna J.D., Yokota J. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007, 26:5911-5918.
47. Gill R.K., Yang S.H., Meerzaman D., Mechanic L.E., Bowman E.D., Jeon H.S., Roy Chowdhuri S., Shakoori A., Dracheva T., Hong K.M., Fukuoka J., Zhang J.H., Harris C.C., Jen J. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 2011, 30:3784-3791.
48. Lunardi A., Ala U., Epping M.T., Salmena L., Clohessy J.G., Webster K.A., Wang G., Mazzucchelli R., Bianconi M., Stack E.C., Lis R., Patnaik A., Cantley L.C., Bubley G., Cordon-Cardo C., Gerald W.L., Montironi R., Signoretti S., Loda M., Nardella C., Pandolfi P.P. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics 2013, 45:747-755.
49. Chang K.H., Li R., Papari-Zareei M., Watumull L., Zhao Y.D., Auchus R.J., Sharifi N. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proceedings of National Academy of Sciences in the United States of America 2011, 108:13728-13733.
50. Pitter K.L., Galban C.J., Galban S., Saeed-Tehrani O., Li F., Charles N., Bradbury M.S., Becher O.J., Chenevert T.L., Rehemtulla A., Ross B.D., Holland E.C., Hambardzumyan D. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS ONE 2011, 6.
51. Chakravarti A., Zhai G., Suzuki Y., Sarkesh S., Black P.M., Muzikansky A., Loeffler J.S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. Journal of Clinical Oncology 2004, 22:1926-1933.
52. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Cora D., Di Nicolantonio F., Buscarino M., Petti C., Ribero D., Russolillo N., Muratore A., Massucco P., Pisacane A., Molinaro L., Valtorta E., Sartore-Bianchi A., Risio M., Capussotti L., Gambacorta M., Siena S., Medico E., Sapino A., Marsoni S., Comoglio P.M., Bardelli A., Trusolino L. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery 2011, 1:508-523.
53. HERACLES TRIAL Institute for Cancer Research and Treatment, 2012.
54. I. Sample, Big pharma mobilising patients in battle over drugs trials data, The Guardian, Guardian News and Media Limited, 2013.
55. Couzin-Frankel J. Unmasking 'invisible' drug trials. Science Insider 2013.
56. Doshi P., Dickersin K., Healy D., Vedula S.S., Jefferson T. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ-British Medical Journal 2013, 346.
57. Frank G. Current Challenges in Clinical Trial Patient Recruitment and Enrollment 2004, SoCRA, SOURCE.
58. Eichenwald K., Kolata G. Drug trials hide conflicts for doctors. N Y Times Web 1999, 1:34.
59. N.I.o.H. National Cancer Institute, Cancer Clinical Trials: The In-Depth Program.
60. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011, 477:526-528.
61. English L.Y., Griffin R. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary 2010, The National Acdemies Press.
62. Fichtner I., Slisow W., Gill J., Becker M., Elbe B., Hillebrand T., Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. European Journal of Cancer 2004, 40:298-307.
63. Krumbach R., Schuler J., Hofmann M., Giesemann T., Fiebig H.H., Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. European Journal of Cancer 2011, 47:1231-1243.
64. Julien S., Merino-Trigo A., Lacroix L., Pocard M., Goere D., Mariani P., Landron S., Bigot L., Nemati F., Dartigues P., Weiswald L.B., Lantuas D., Morgand L., Pham E., Gonin P., Dangles-Marie V., Job B., Dessen P., Bruno A., Pierre A., De The H., Soliman H., Nunes M., Lardier G., Calvet L., Demers B., Prevost G., Vrignaud P., Roman-Roman S., Duchamp O., Berthet C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clinical Cancer Research 2012, 18:5314-5328.
65. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proceedings of National Academy of Sciences in the United States of America 2007, 104:10158-10163.
66. Zhu H., Zhou W., Hu J., Huang Z., Lao W., Huang X., He C. Suppressing the growth of rectal cancer xenografts derived from patient tumors by an adenovector expressing small hairpin RNA targeting Bcl-XL. Journal of Genetics Medicine 2012, 14:761-768.
67. Jin K.T., Li G.L., Cui B.B., Zhang J., Lan H.R., Han N., Xie B.J., Cao F.L., He K.F., Wang H.H., Xu Z.Z., Teng L.S., Zhu T.M. Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS ONE 2011, 6.
68. Jin K., Lan H., Cao F., Han N., Xu Z., Li G., He K., Teng L. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. International Journal of Oncology 2012, 41:583-588.
69. Zhou W., Zhu H., Chen W., Hu X., Pang X., Zhang J., Huang X., Fang B., He C. Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus. Cancer Gene Therapy 2011, 18:336-345.
70. Ducker G.S., Atreya C.E., Simko J.P., Hom Y.K., Matli M.R., Benes C.H., Hann B., Nakakura E.K., Bergsland E.K., Donner D.B., Settleman J., Shokat K.M., Warren R.S. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2013.
71. Uronis J.M., Osada T., McCall S., Yang X.Y., Mantyh C., Morse M.A., Lyerly H.K., Clary B.M., Hsu D.S. Histological and molecular evaluation of patient-derived colorectal cancer explants. PLoS ONE 2012, 7:e38422.
72. Garrido-Laguna I., Tan A.C., Uson M., Angenendt M., Ma W.W., Villaroel M.C., Zhao M., Rajeshkumar N.V., Jimeno A., Donehower R., Iacobuzio-Donahue C., Barrett M., Rudek M.A., Rubio-Viqueira B., Laheru D., Hidalgo M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. British Journal of Cancer 2010, 103:649-655.
73. Jimeno A., Rubio-Viqueira B., Rajeshkumar N.V., Chan A., Solomon A., Hidalgo M. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. Molecular Cancer Therapeutics 2010, 9:311-318.
74. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., Zhang H., Soon-Shiong P., Shi T., Rajeshkumar N.V., Maitra A., Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology 2011, 29:4548-4554.
75. Walters L.J., Adair D.M., Newhook S.J., Cowan T.E., Stokes C.R., Borgman J.B., Stelow C.A., Lowrey E.B., Chopivsky B.T., Gilmer M.E., Parsons T.M., Bauer J.T. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 Inhibitor lapatinib. Neoplasia 2013, 15:143-155.
76. Villarroel M.C., Rajeshkumar N.V., Garrido-Laguna I., De Jesus-Acosta A., Jones S., Maitra A., Hruban R.H., Eshleman J.R., Klein A., Laheru D., Donehower R., Hidalgo M. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Molecular Cancer Therapeutics 2011, 10:3-8.
77. A Combination of TH-302 and Radiation Reduced Human Pancreatic Tumor Growth in Hypoxic Xenografts, American Association for Cancer Research AACR Press Releases, Lake Tahoe, Nevada, USA, 2012.
78. Laheru D., Shah P., Rajeshkumar N.V., McAllister F., Taylor G., Goldsweig H., Le D.T., Donehower R., Jimeno A., Linden S., Zhao M., Song D., Rudek M.A., Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Investigational New Drugs 2012, 30:2391-2399.
79. Walters D.M., Lindberg J.M., Adair S.J., Newhook T.E., Cowan C.R., Stokes J.B., Borgman C.A., Stelow E.B., Lowrey B.T., Chopivsky M.E., Gilmer T.M., Parsons J.T., Bauer T.W. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 2013, 15:143-U207.
80. Venkatesha V.A., Parsels L.A., Parsels J.D., Zhao L.L., Zabludoff S.D., Simeone D.M., Maybaum J., Lawrence T.S., Morgan M.A. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 2012, 14:519-525.
81. John T., Kohler D., Pintilie M., Yanagawa N., Pham N.A., Li M., Panchal D., Hui F., Meng F.N., Shepherd F.A., Tsao M.S. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clinical Cancer Research 2011, 17:134-141.
82. Zhang J.C., Zhang L., Su X.Y., Li M., Xie L., Malchers F., Fan S.Q., Yin X.L., Xu Y.P., Liu K.J., Dong Z.W., Zhu G.S., Qian Z.L., Tang L.L., Zhan P., Ji Q.S., Kilgour E., Smith P.D., Brooks A.N., Thomas R.K., Gavine P.R. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clinical Cancer Research 2012, 18:6658-6667.
83. Fiebig H.H., Schuler J., Bausch N., Hofmann M., Metz T., Korrat A. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics & Proteomics 2007, 4:197-209.
84. Nemati F., Sastre-Garau X., Laurent C., Couturier J., Mariani P., Desjardins L., Piperno-Neumann S., Lantz O., Asselain B., Plancher C., Robert D., Peguillet I., Donnadieu M.H., Dahmani A., Bessard M.A., Gentien D., Reyes C., Saule S., Barillot E., Roman-Roman S., Decaudin D. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clinical Cancer Research 2010, 16:2352-2362.
85. Moestue S.A., Borgan E., Huuse E.M., Lindholm E.M., Sitter B., Borresen-Dale A.L., Engebraaten O., Maelandsmo G.M., Gribbestad I.S. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10:433.
86. de Plater L., Lauge A., Guyader C., Poupon M.F., Assayag F., de Cremoux P., Vincent-Salomon A., Stoppa-Lyonnet D., Sigal-Zafrani B., Fontaine J.J., Brough R., Lord C.J., Ashworth A., Cottu P., Decaudin D., Marangoni E. Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. British Journal of Cancer 2010, 103:1192-1200.
87. Kabos P., Finlay-Schultz J., Li C., Kline E., Finlayson C., Wisell J., Manuel C.A., Edgerton S.M., Harrell J.C., Elias A., Sartorius C.A. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Research and Treatment 2012, 135:415-432.
88. Fleming J.M., Miller T.C., Meyer M.J., Ginsburg E., Vonderhaar B.K. Local regulation of human breast xenograft models. Journal of Cellular Physiology 2010, 224:795-806.
89. Romanelli A., Clark A., Assayag F., Chateau-Joubert S., Poupon M.F., Servely J.L., Fontaine J.J., Liu X., Spooner E., Goodstal S., de Cremoux P., Bieche I., Decaudin D., Marangoni E. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Molecular Cancer Therapeutics 2012, 11:2693-2703.
90. Cottu T.B., Assayag F., Bièche I., Chateau-Joubert S., Fontaine J.-J., Decaudin D., Slimane K., Vincent-Salomon A., Marangoni E. Targeting the PI3K/mTOR Pathway in Patient-Derived Xenograft Models of Endocrine Resistant Luminal Breast Cancer 2012, American Association for Cancer Research, San Antonio, Texas.
91. M-E Legrier V.Y., Beurdeley A., Stephant G., Le Ven E., Banis S., Lassalle M., Deas O., Cairo S., Judde J.-G. Early Activation of IFN/STAT Signaling in Tumor Cells of Patient-Derived Triple Negative Breast Cancer Xenografts Predicts Tumor Sensitivity to Chemotherapy 2012, American Association for Cancer Research, San Antonio, Texas, USA.
92. Serra V., Eichhorn P.J.A., Garcia-Garcia C., Ibrahim Y.H., Prudkin L., Sanchez G., Rodriguez O., Anton P., Parra J.L., Marlow S., Scaltriti M., Perez-Garcia J., Prat A., Arribas J., Hahn W.C., Kim S.Y., Baselga J. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation 2013, 123:2551-2563.
93. Karam J.A., Zhang X.Y., Tamboli P., Margulis V., Wang H., Abel E.J., Culp S.H., Wood C.G. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. European Urology 2011, 59:619-628.
94. Yuen J.S., Sim M.Y., Siml H.G., Chong T.W., Lau W.K., Cheng C.W., Huynh H. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. British Journal of Cancer 2011, 104:941-947.
95. Hammers H.J., Verheul H.M., Salumbides B., Sharma R., Rudek M., Jaspers J., Shah P., Ellis L., Shen L., Paesante S., Dykema K., Furge K., Teh B., Netto G., Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular Cancer Therapeutics 2010, 9:1525-1535.
96. Wu X., Zhang J., Zhen R., Lv J., Zheng L., Su X., Zhu G., Gavine P.R., Xu S., Lu S., Hou J., Liu Y., Xu C., Tan Y., Xie L., Yin X., He D., Ji Q., Hou Y., Ge D. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. Journal of Translational Medicine 2012, 10:180.
97. Oudard S., Legrier M.E., Boye K., Bras-Goncalves R., De Pinieux G., De Cremoux P., Poupon M.F. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. Journal of Urology 2003, 169:1729-1734.
98. Raheem O., Kulidjian A.A., Wu C., Jeong Y.B., Yamaguchi T., Smith K.M., Goff D., Leu H., Morris S.R., Cacalano N.A., Masuda K., Jamieson C.H.M., Kane C.J., Jamieson C.A.M. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. Journal of Translational Medicine 2011, 9.
99. Kortmann U., McAlpine J.N., Xue H., Guan J., Ha G., Tully S., Shafait S., Lau A., Cranston A.N., O'Connor M.J., Huntsman D.G., Wang Y., Gilks C.B. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clinical Cancer Research 2011, 17:783-791.
100. Bankert R.B., Balu-Iyer S.V., Odunsi K., Shultz L.D., Kelleher R.J., Barnas J.L., Simpson-Abelson M., Parsons R., Yokota S.J. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 2011, 6:e24420.
101. Chaudary N., Pintilie M., Schwock J., Dhani N., Clarke B., Milosevic M., Fyles A., Hill R.P. Characterization of the tumor-microenvironment in patient-derived cervix xenografts (OCICx). Cancers 2012, 4:821-845.
102. Hennessey P.T., Ochs M.F., Mydlarz W.W., Hsueh W., Cope L., Yu W.N., Califano J.A. Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS ONE 2011, 6.
103. Keysar S.B., Le P.N., Anderson R.T., Morton J.J., Bowles D.W., Paylor J.J., Vogler B.W., Thorburn J., Fernandez P., Glogowska M.J., Takimoto S.M., Sehrt D.B., Gan G.N., Eagles-Soukup J.R., Serracino H., Hirsch F.R., Lucia M.S., Thorburn A., Song J.I., Wang X.J., Jimeno A. Hedgehog signaling alters reliance on egf receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Research 2013, 73:3381-3392.
104. Jin K.T., Lan H.R., Cao F.L., Xu Z.Z., Han N., Li G.L., He K.F., Teng L.S. Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism. Oncology Letters 2012, 3:1052-1058.
105. Liu Z., Zhao X., Mao H., Baxter P.A., Huang Y., Yu L., Wadhwa L., Su J.M., Adesina A., Perlaky L., Hurwitz M., Idamakanti N., Police S.R., Hallenbeck P.L., Hurwitz R.L., Lau C.C., Chintagumpala M., Blaney S.M., Li X.N. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neurological Oncology 2013.
106. Johansson M., Oudin A., Tiemann K., Bernard A., Golebiewska A., Keunen O., Fack F., Stieber D., Wang B., Hedman H., Niclou S.P. The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neurological Oncology 2013.
107. Wong J.C., Tang G., Wu X., Liang C., Zhang Z., Guo L., Peng Z., Zhang W., Lin X., Wang Z., Mei J., Chen J., Pan S., Zhang N., Liu Y., Zhou M., Feng L., Zhao W., Li S., Zhang C., Zhang M., Rong Y., Jin T.G., Zhang X., Ren S., Ji Y., Zhao R., She J., Ren Y., Xu C., Chen D., Cai J., Shan S., Pan D., Ning Z., Lu X., Chen T., He Y., Chen L. Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. Journal of Medicinal Chemistry 2012, 55:8903-8925.
108. Terziyska N., Castro Alves C., Groiss V., Schneider K., Farkasova K., Ogris M., Wagner E., Ehrhardt H., zur Stadt U., Horstmann M., Quintanilla-Martinez L., Jeremias I. In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. PLoS ONE 2012, 7:e52798.